Heart and blood vessel health in cystic fibrosis
Part of Digestive system, Genetic & congenital, Heart & circulation, Lungs & breathing clinical trials.
This study looks at how cystic fibrosis and gene modulator treatments affect the health of your heart and blood vessels. By joining, you'll help researchers understand these effects and potentially improve care for people with CF.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of cystic fibrosis (via sweat test or genetic testing).
- You must be 18 years or older.
- You must currently take a gene modulator medicine (like elexacaftor/tezacaftor/ivacaftor or a newer one) and have been for at least 3 months.
- You must be clinically stable, meaning no lung flare-ups or hospital admissions in the past 4 weeks.
- You must not be a smoker or have smoked in the last 10 years, and you must not have had an organ transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether doing remote (home-based) exercise can improve your physical activity levels and heart health if you have cystic fibrosis. You'll be guided through exercises from home, and the researchers will see if this helps your heart and overall well-being.
This study aims to understand what causes and increases the risk of lung infections (exacerbations) in people with cystic fibrosis. It involves regular monitoring and sample collection at home and in the clinic to identify early warning signs.
This study looks at how long-term diabetes affects people with cystic fibrosis. It helps researchers understand complications and improve care.
This trial compares physical abilities between children with cystic fibrosis and healthy children. It aims to find differences that could lead to better care and therapies.
This study measures how often people with cystic fibrosis who take elexacaftor-tezacaftor-ivacaftor (ETI) experience breathing limitations during exercise and what factors are linked to this.
This study looks at new, advanced tests to help doctors better diagnose cystic fibrosis in people whose current test results are not clear. Participation involves a rectal biopsy, which helps researchers study how the CFTR protein works in the body.
Hear when a new Cardiovascular (CV) Risk trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.